Logo image
Back
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma
Journal article   Open access   Peer reviewed

Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma

Brian J. O’Connor, Claes-Göran Löfdahl, Meyer Balter, Andrew Szczeklik, Louis-Philippe Boulet and Charles B. Cairns
Respiratory medicine, v 101(6), pp 1088-1096
01 Jun 2007
DOI: https://doi.org/10.1016/j.rmed.2007.01.017
PMID: 17360171
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.rmed.2007.01.017View
Published, Version of Record (VoR) Open

Abstract

5-lipoxygenase 5-lipoxygenase inhibition Asthma Beclomethasone Ltb 4 Zileuton
To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms. Randomized, active-control, double-blind, parallel, multi-center study of zileuton (400 or 600 mg QID)+200 μg beclomethasone dipropionate (BDP) BID versus placebo+BDP 400 μg BID in asthmatics with baseline FEV 1 percent predicted values between 40% and 80% following a single-blind ICS (BDP 200 μg BID) 2-week run-in. During the 3-month double-blind treatment period, assessments included safety, daytime and nighttime symptoms, acute asthma exacerbations, β 2-agonist use, AM and PM peak expiratory flow (PEF) and FEV 1. The addition of a 5-lipoxygenase (5-LO) inhibitor added to a low-dose of BDP showed no significant difference in FEV 1 compared to doubling the dose of BDP. FEV 1 improved in all 3 treatment groups, with mean increases of 10% with zileuton 600 mg QID+BDP 200 μg BID, 12% with zileuton 400 mg QID+BDP 200 μg BID, and 11% with BDP 400 μg BID by study end. Within each treatment group, there were significant improvements in asthma symptoms and AM and PM PEF compared to baseline. No significant differences were observed between groups with regards to salbutamol use, acute asthma exacerbations, the requirement for oral/parenteral corticosteroids and adverse clinical events. The addition of a 5-LO inhibitor added to low-dose beclomethasone may be an alternative to higher-doses of ICS in patients unable to achieve sufficient asthma control on low-dose ICS therapy.

Metrics

7 Record Views
15 citations in Web of Science
17 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Respiratory System
Logo image